-$1.06 EPS Expected for Insmed Incorporated (INSM) This Quarter

Wall Street brokerages expect Insmed Incorporated (NASDAQ:INSM) to report earnings per share of ($1.06) for the current quarter, according to Zacks. Zero analysts have issued estimates for Insmed’s earnings, with the highest EPS estimate coming in at ($1.02) and the lowest estimate coming in at ($1.12). Insmed reported earnings per share of ($0.69) in the same quarter last year, which would suggest a negative year over year growth rate of 53.6%. The company is scheduled to issue its next earnings report on Thursday, November 1st.

On average, analysts expect that Insmed will report full year earnings of ($4.05) per share for the current financial year, with EPS estimates ranging from ($4.19) to ($3.89). For the next financial year, analysts expect that the firm will report earnings of ($3.44) per share, with EPS estimates ranging from ($4.84) to ($2.48). Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side analysts that cover Insmed.

Insmed (NASDAQ:INSM) last announced its quarterly earnings results on Thursday, August 2nd. The biopharmaceutical company reported ($1.00) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.08) by $0.08.

Several research firms have recently commented on INSM. BidaskClub lowered shares of Insmed from a “buy” rating to a “hold” rating in a research note on Tuesday, June 26th. ValuEngine lowered shares of Insmed from a “buy” rating to a “hold” rating in a research note on Tuesday, October 2nd. Zacks Investment Research raised shares of Insmed from a “hold” rating to a “buy” rating and set a $28.00 price objective for the company in a research note on Wednesday, July 4th. Goldman Sachs Group began coverage on shares of Insmed in a research note on Monday, July 23rd. They issued a “neutral” rating and a $32.00 price objective for the company. Finally, HC Wainwright reissued a “buy” rating and issued a $43.00 price objective on shares of Insmed in a research note on Friday, August 3rd. Five equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $38.14.

A number of institutional investors have recently modified their holdings of INSM. Palo Alto Investors LP lifted its stake in Insmed by 11.8% in the first quarter. Palo Alto Investors LP now owns 7,159,590 shares of the biopharmaceutical company’s stock worth $161,234,000 after acquiring an additional 755,004 shares during the last quarter. Foresite Capital Management II LLC lifted its stake in Insmed by 86.6% in the first quarter. Foresite Capital Management II LLC now owns 967,636 shares of the biopharmaceutical company’s stock worth $21,791,000 after acquiring an additional 448,991 shares during the last quarter. Nexthera Capital LP lifted its stake in Insmed by 84.1% in the first quarter. Nexthera Capital LP now owns 918,523 shares of the biopharmaceutical company’s stock worth $20,685,000 after acquiring an additional 419,602 shares during the last quarter. Voya Investment Management LLC lifted its stake in Insmed by 31.9% in the second quarter. Voya Investment Management LLC now owns 1,053,468 shares of the biopharmaceutical company’s stock worth $24,914,000 after acquiring an additional 254,853 shares during the last quarter. Finally, Summit Trail Advisors LLC purchased a new position in Insmed in the first quarter worth approximately $250,000.

Shares of NASDAQ INSM traded up $1.09 during midday trading on Tuesday, hitting $17.51. The company’s stock had a trading volume of 768,700 shares, compared to its average volume of 891,017. The company has a debt-to-equity ratio of 0.83, a quick ratio of 14.14 and a current ratio of 14.14. Insmed has a 1 year low of $15.30 and a 1 year high of $33.94. The firm has a market cap of $1.56 billion, a price-to-earnings ratio of -5.65 and a beta of 1.30.

Insmed Company Profile

Insmed Incorporated, a biopharmaceutical company, focuses on the development and commercialization of therapies for patients with rare diseases. The company's lead product candidate is amikacin liposome inhalation suspension, which is in late-state development for adult patients with treatment refractory nontuberculous mycobacteria lung disease caused by mycobacterium avium complex.

Read More: Google Finance Portfolio Workaround

Get a free copy of the Zacks research report on Insmed (INSM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Insmed (NASDAQ:INSM)

Receive News & Ratings for Insmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply